Holen Sie sich die Stockscreener-App
5.06
12.69%
0.57
Vorhandelsmarkt:
5.05
-0.010
-0.20%
Schlusskurs vom Vortag:
$4.49
Offen:
$4.82
24-Stunden-Volumen:
5.02M
Relative Volume:
0.80
Marktkapitalisierung:
$1.39B
Einnahmen:
$8.10M
Nettoeinkommen (Verlust:
$-92.72M
KGV:
-14.17
EPS:
-0.3571
Netto-Cashflow:
$-82.52M
1W Leistung:
+4.12%
1M Leistung:
+18.50%
6M Leistung:
+81.36%
1J Leistung:
+106.11%
1-Tages-Spanne:
$4.645
$5.095
1-Wochen-Bereich:
$4.03
$5.095
52-Wochen-Spanne:
$1.05
$5.5082
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Firmenname
Taysha Gene Therapies Inc
Sektor
Branche
Telefon
(214) 612-0000
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Vergleichen Sie TSHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
5.06 | 1.23B | 8.10M | -92.72M | -82.52M | -0.3571 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-11 | Eingeleitet | BofA Securities | Buy |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-04-09 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-01 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-03-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-03-01 | Eingeleitet | Wells Fargo | Overweight |
| 2022-02-18 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | Guggenheim | Buy |
| 2021-07-16 | Eingeleitet | Needham | Buy |
| 2021-06-24 | Eingeleitet | Truist | Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-06-09 | Eingeleitet | Wedbush | Outperform |
| 2021-06-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Fortgesetzt | Jefferies | Buy |
| 2021-02-24 | Eingeleitet | William Blair | Outperform |
| 2021-01-05 | Eingeleitet | Oppenheimer | Outperform |
| 2020-10-19 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-19 | Eingeleitet | Goldman | Buy |
| 2020-10-19 | Eingeleitet | Jefferies | Buy |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Taysha Gene Therapies Inc Aktie (TSHA) Neueste Nachrichten
Taysha Gene Therapies (TSHA) Upgraded to Buy by Goldman Sachs - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 7%Still a Buy? - MarketBeat
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - Seeking Alpha
Taysha Gene Therapies (TSHA) Receives Buy Rating from Goldman Sa - GuruFocus
Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 6.5% on Insider Selling - MarketBeat
How Taysha Gene Therapies Inc. stock reacts to oil prices2025 EndofYear Setup & Technical Confirmation Alerts - Newser
Sukumar Nagendran Sells 260,047 Shares of Taysha Gene Therapies (NASDAQ:TSHA) Stock - MarketBeat
Taysha Gene Therapies Insider Sold Shares Worth $1,695,906, According to a Recent SEC Filing - marketscreener.com
Nagendran Sukumar sells Taysha gene therapies (TSHA) shares for $1.69m - Investing.com Canada
TSHA FY2026 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
How analysts rate Taysha Gene Therapies Inc. stock todayQuarterly Portfolio Summary & Safe Capital Growth Trade Ideas - BỘ NỘI VỤ
Will breakout in Taysha Gene Therapies Inc. lead to full recoveryQuarterly Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
Using Bollinger Bands to evaluate Taysha Gene Therapies Inc.Portfolio Return Report & Growth-Oriented Investment Plans - newser.com
Custom watchlist performance reports with Taysha Gene Therapies Inc.2025 Geopolitical Influence & Fast Entry Momentum Alerts - newser.com
Will Taysha Gene Therapies Inc. stock recover after recent dropWeekly Risk Report & Safe Capital Preservation Plans - newser.com
How Taysha Gene Therapies Inc. stock benefits from strong dollarJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Why Taysha Gene Therapies Inc. stock is favored by top institutionsJuly 2025 Technicals & Free Long-Term Investment Growth Plans - newser.com
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? - MSN
11 Must-Buy Penny Stocks to Buy Now - Insider Monkey
Is Taysha Gene Therapies Inc. stock near bottom after declineJuly 2025 Opening Moves & AI Based Buy/Sell Signal Reports - newser.com
Can Taysha Gene Therapies Inc. hit a new high this monthTrade Ideas & Weekly High Momentum Picks - newser.com
Can Taysha Gene Therapies Inc. stock sustain institutional interestJuly 2025 Retail & Short-Term Trading Alerts - newser.com
Candlestick signals on Taysha Gene Therapies Inc. stock todayJuly 2025 Intraday Action & Daily Profit Focused Screening - newser.com
Detecting support and resistance levels for Taysha Gene Therapies Inc.Market Performance Summary & Real-Time Stock Entry Alerts - newser.com
Will a bounce in Taysha Gene Therapies Inc. offer an exitJuly 2025 Technicals & Real-Time Volume Triggers - newser.com
Cantor Fitzgerald maintains Overweight rating on Taysha Gene Therapies stock - Investing.com Canada
Why Taysha Gene Therapies Inc. stock is rated strong buyRate Hike & Precise Swing Trade Entry Alerts - newser.com
Taysha Gene Therapies Experiences Revision in Its Stock Evaluation Amid Mixed Performance Metrics - Markets Mojo
Finanzdaten der Taysha Gene Therapies Inc-Aktie (TSHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):